Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression

[1]  R. Prasad,et al.  Expression profile of H3K4 demethylases with their clinical and pathological correlation in patients with clear cell renal cell carcinoma. , 2020, Gene.

[2]  F. Jiao,et al.  Lysine demethylase 2 (KDM2B) regulates hippo pathway via MOB1 to promote pancreatic ductal adenocarcinoma (PDAC) progression , 2020, Journal of experimental & clinical cancer research : CR.

[3]  Zachary T Herbert,et al.  The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis , 2019, Genes & development.

[4]  M. Fallon,et al.  A novel KDM5A/MPC-1 signaling pathway promotes pancreatic cancer progression via redirecting mitochondrial pyruvate metabolism , 2019, Oncogene.

[5]  A. Hergovich,et al.  MOB (Mps one Binder) Proteins in the Hippo Pathway and Cancer , 2019, Cells.

[6]  E. Giovannucci,et al.  The Epidemiology of Prostate Cancer. , 2018, Cold Spring Harbor perspectives in medicine.

[7]  Zhike Lu,et al.  Ythdf2-mediated m6A mRNA clearance modulates neural development in mice , 2018, Genome Biology.

[8]  Liping Xie,et al.  Downregulation of N6-methyladenosine binding YTHDF2 protein mediated by miR-493-3p suppresses prostate cancer by elevating N6-methyladenosine levels , 2017, Oncotarget.

[9]  F. Du,et al.  YTH domain family 2 orchestrates epithelial-mesenchymal transition/proliferation dichotomy in pancreatic cancer cells , 2017, Cell cycle.

[10]  Yan Wang,et al.  KDM5A promotes proliferation and EMT in ovarian cancer and closely correlates with PTX resistance. , 2017, Molecular medicine reports.

[11]  Mark S. Litwin,et al.  The Diagnosis and Treatment of Prostate Cancer: A Review , 2017, JAMA.

[12]  J. Merkel,et al.  Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance , 2016, Oncotarget.

[13]  Wanjia Xu,et al.  MicroRNA-495 Regulates Migration and Invasion in Prostate Cancer Cells Via Targeting Akt and mTOR Signaling , 2016, Cancer investigation.

[14]  D. Srivastava,et al.  microRNAs as Developmental Regulators. , 2015, Cold Spring Harbor perspectives in biology.

[15]  Won Tae Kim,et al.  Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics , 2015, Journal of Korean medical science.

[16]  Lu‐Hai Wang,et al.  Regulation of cancer metastasis by microRNAs , 2015, Journal of Biomedical Science.

[17]  Jiping Zeng,et al.  Histone demethylase RBP2 decreases miR-21 in blast crisis of chronic myeloid leukemia , 2014, Oncotarget.

[18]  A. Levine,et al.  MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells , 2014, Oncogene.

[19]  J. Ramalho-Carvalho,et al.  Deregulated expression of selected histone methylases and demethylases in prostate carcinoma. , 2013, Endocrine-related cancer.

[20]  A. Mai,et al.  The emerging role of histone lysine demethylases in prostate cancer , 2012, Molecular Cancer.

[21]  Muhammad Naeem Bashir.  Epidemiology of Prostate Cancer. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[22]  Jinling Hou,et al.  Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer. , 2012, American journal of translational research.